Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives $8.00 Consensus Price Target from Brokerages

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) has been given a consensus rating of “Moderate Buy” by the seven ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $8.00.

Several brokerages recently commented on HOWL. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Citigroup reiterated a “buy” rating on shares of Werewolf Therapeutics in a research report on Monday, August 25th. Bank of America reduced their price target on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, August 25th. JMP Securities lowered their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a report on Thursday, August 21st. Finally, Zacks Research raised Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th.

Werewolf Therapeutics Stock Performance

NASDAQ HOWL opened at $1.13 on Friday. The stock has a market capitalization of $54.85 million, a price-to-earnings ratio of -0.70 and a beta of 0.72. The stock has a 50-day moving average of $1.60 and a 200 day moving average of $1.33. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics has a twelve month low of $0.60 and a twelve month high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. Sell-side analysts anticipate that Werewolf Therapeutics will post -1.56 EPS for the current fiscal year.

Insider Activity at Werewolf Therapeutics

In other Werewolf Therapeutics news, Director Luke Evnin sold 90,164 shares of the firm’s stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $1.22, for a total value of $110,000.08. Following the transaction, the director owned 3,853,195 shares in the company, valued at approximately $4,700,897.90. This trade represents a 2.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Bioventures 2014 L.P. Mpm sold 140,488 shares of Werewolf Therapeutics stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $1.22, for a total transaction of $171,395.36. Following the sale, the insider directly owned 6,007,122 shares in the company, valued at approximately $7,328,688.84. This trade represents a 2.29% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 2,150,286 shares of company stock valued at $2,995,317. 23.60% of the stock is owned by insiders.

Institutional Trading of Werewolf Therapeutics

Several large investors have recently bought and sold shares of HOWL. MPM Bioimpact LLC raised its holdings in Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after acquiring an additional 20,799 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Werewolf Therapeutics by 33.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock valued at $93,000 after purchasing an additional 23,852 shares in the last quarter. MPM Asset Management LLC increased its holdings in shares of Werewolf Therapeutics by 0.6% in the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after purchasing an additional 25,688 shares during the last quarter. Quadrature Capital Ltd acquired a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $28,000. Finally, Bank of America Corp DE lifted its position in Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after buying an additional 25,882 shares in the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.